We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+15.59%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$664M
AUM Growth
+$96.5M
Cap. Flow
+$35.6M
Cap. Flow %
5.35%
Top 10 Hldgs %
45.17%
Holding
73
New
23
Increased
14
Reduced
10
Closed
23

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$37.5M
2
AGN
Allergan plc
AGN
+$36.2M
3
STJ
St Jude Medical
STJ
+$33.9M
4
GILD icon
Gilead Sciences
GILD
+$31.7M
5
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$27.4M

Top Sells

Rank Stock Value
1
ALGN icon
Align Technology
ALGN
+$38.8M
2
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$34.2M
3
CAH icon
Cardinal Health
CAH
+$27.6M
4
IPXL
Impax Laboratories, Inc.
IPXL
+$19.2M
5
CELG
Celgene Corp
CELG
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 80.5%
2 Miscellaneous 17.62%
3 Consumer Staples 1.19%
4 Technology 0.69%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARTC
26
DELISTED
ARTHROCARE CORP
ARTC
$12.2M 1.84%
+342,759
New +$12M
TRNX
27
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$11M 1.65%
568,100
+19,000
+3% +$353K
KYTH
28
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$10.4M 1.57%
228,218
+118,100
+107% +$3.53M
PACB icon
29
Pacific Biosciences
PACB
$435M
$8.71M 1.31%
1,574,379
-876,201
-36% -$3.04M
TVTY
30
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$8.57M 1.29%
+462,913
New +$8.37M
NSTG
31
DELISTED
NanoString Technologies, Inc.
NSTG
$8.29M 1.25%
+754,132
New +$6.82M
VRTX icon
32
Vertex Pharmaceuticals
VRTX
$137B
$8.21M 1.24%
+108,262
New +$8.61M
ARAY icon
33
Accuray
ARAY
$32.7M
$7.93M 1.2%
+1,073,799
New +$6.79M
WOOF
34
DELISTED
VCA Inc.
WOOF
$7.91M 1.19%
288,000
+10,000
+4% +$280K
BSTC
35
DELISTED
BioSpecifics Technologies Corp.
BSTC
$6.36M 0.96%
326,652
+14,500
+5% +$257K
FOLD
36
DELISTED
Amicus Therapeutics
FOLD
$5.74M 0.86%
2,473,787
+100,100
+4% +$251K
NUWE icon
37
Nuwellis
NUWE
$2.82M
– –
0
– –
PGEN icon
38
Precigen
PGEN
$2.49B
$4.82M 0.73%
+213,033
New +$4.92M
VCRA
39
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$4.56M 0.69%
+245,400
New +$3.99M
AMRN
40
Amarin Corp
AMRN
$295M
$4.11M 0.62%
+32,485
New +$3.89M
GWPH
41
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.86M 0.43%
+165,020
New +$1.89M
AGIO icon
42
Agios Pharmaceuticals
AGIO
$1.99B
$1.49M 0.22%
+53,100
New +$1.47M
RCPT
43
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$540K 0.08%
+20,800
New +$400K
VSTM icon
44
Verastem
VSTM
$654M
$386K 0.06%
+2,583
New +$451K
PPH icon
45
VanEck Pharmaceutical ETF
PPH
$993M
$311K 0.05%
6,500
– –
RPRX
46
DELISTED
Repros Therapeutics Inc.
RPRX
$281K 0.04%
+10,500
New +$225K
AGN
47
DELISTED
Allergan Inc
AGN
$238K 0.04%
2,627
-124,400
-98% -$11.2M
PRGO icon
48
Perrigo
PRGO
$2.01B
$210K 0.03%
+1,700
New +$212K
MRK icon
49
Merck
MRK
$366B
$90K 0.01%
+1,991
New +$90.9K
ABT icon
50
Abbott
ABT
$195B
– –
-7,200
Closed -$251K
1
2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2013 Portfolio in Review

As of Q3 2013, Redmile Group held 73 positions worth $664M, up 17% from $568M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Redmile Group deployed $35.6M of net new capital in Q3 2013, opening 23 new positions and adding to 14 existing holdings. Its largest new stake was Amgen: 345,700 shares worth $38.7M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 81% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Celgene Corp, an estimated $14.3M trimmed.

  • Redmile Group's largest Q3 2013 buy was Amgen: 345,700 shares worth $38.7M.
  • Redmile Group added most to Tenet Healthcare in Q3 2013, an estimated $11.5M increase.
  • Redmile Group's biggest Q3 2013 reduction was Celgene Corp, cutting an estimated $14.3M.
  • Redmile Group fully exited Align Technology in Q3 2013, selling an estimated $38.8M.
  • Redmile Group's ten largest holdings make up 45% of its $664M portfolio in Q3 2013.
  • Redmile Group opened 23 new positions and closed 23 in Q3 2013.
  • Redmile Group's portfolio value rose 17% quarter-over-quarter to $664M.

Based on Redmile Group's 13F filing for Q3 2013, filed 14 Nov 2013.